The SGLT2 Inhibitor Empagliflozin Ameliorates the Inflammatory Profile in Type 2 Diabetic Patients and Promotes an Antioxidant Response in Leukocytes

Sodium–glucose co-transporter 2 inhibitors (iSGLT2) have been linked to a considerable reduction in cardiovascular risk in patients with type 2 diabetes (T2D), but the precise molecular mechanisms are still elusive. We aimed to evaluate the effects of the iSGLT2 empagliflozin on systemic inflammatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannantuoni, Francesca, M. de Marañon, Aranzazu, Diaz-Morales, Noelia, Falcon, Rosa, Bañuls, Celia, Abad-Jimenez, Zaida, Victor, Victor M., Hernandez-Mijares, Antonio, Rovira-Llopis, Susana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912454/
https://www.ncbi.nlm.nih.gov/pubmed/31683785
http://dx.doi.org/10.3390/jcm8111814

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912454/
https://www.ncbi.nlm.nih.gov/pubmed/31683785
http://dx.doi.org/10.3390/jcm8111814

Ejemplares similares